Merck wins OTC switch for OAB drug Oxytrol for US women; men still need Rx
This article was originally published in Scrip
Executive Summary
The US FDA granted its blessing to Merck on 25 January to switch its overactive bladder medicine Oxytrol (oxybutynin transdermal system, 3.9 mg/day) from a prescription product to over-the-counter (OTC) for use in women.